... Annual and special meeting of shareholders set for May 23 2008...TORONTO April 24 / DRAXIS Health Inc.( DRAXIS...The record date for determining the holders of common shares of DRAXIS...The Notice of Annual and Special Meeting and Management InformationCi...

TORONTO, April 24 /PRNewswire-FirstCall/ - DRAXIS Health Inc.
("DRAXIS") (TSX: DAX) (NASDAQ: DRAX) announced today that it has obtained
an Interim Order from the Quebec Superior Court in connection with the
proposed statutory arrangement under which all of DRAXIS' common shares
will be acquired by a subsidiary of Jubilant Organosys Ltd ("Jubilant") for
US$6.00 per common share. The arrangement will be considered at the annual
and special meeting of DRAXIS shareholders scheduled to be held at 10:00
a.m. (Toronto time) on Friday, May 23, 2008 at the offices of McCarthy
Tetrault LLP, Suite 5300, TD Bank Tower, Toronto, Ontario, Canada.

The record date for determining the holders of common shares of DRAXIS
entitled to receive notice of and to vote at the annual and special meeting
of shareholders is the close of business on April 24, 2008.

The Notice of Annual and Special Meeting and Management Information
Circular relating to the meeting will be mailed to DRAXIS shareholders
shortly. Once mailed, the Management Information Circular will be available
at http://www.sedar.com and http://www.sec.gov, as well as on DRAXIS' website at
http://www.draxis.com. The Circular provides important information about the
proposed plan of arrangement, as well as important information regarding
voting procedures. All shareholders are urged to read the Circular once it
is available.

About DRAXIS Health Inc.:

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS
Specialty Pharmaceuticals Inc., provides products in three categories:
sterile products, non-sterile products and radiopharmaceuticals. Sterile
products include liquid and freeze-dried (lyophilized) injectables plus
sterile ointments and creams. Non-sterile products are produced as solid
oral and semi-solid dosage forms. Radiopharmaceuticals are used for both
therapeutic and diagnostic molecular imaging applications. Pharmaceutical
contract manufacturing services are provided through the DRAXIS Pharma
division and radiopharmaceuticals are developed, produced, and sold through
the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its
Montreal facility.
For additional information please visit http://www.draxis.com

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act") and Section 21E of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and as contemplated under other applicable
securities legislation. These statements can be identified by the use of
forward-looking terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "plan," "intend," "believe" or other similar words.
These statements discuss future expectations concerning results of
operations or financial condition or provide other forward-looking
information. Our actual results, performance or achievements could be
significantly different from the results expressed in, or implied by, those
forward-looking statements. You should not place undue reliance on any
forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their
nature, forward-looking statements involve numerous assumptions, known and
unknown risks, uncertainties and other factors that may cause the actual
results or performance of the Company to be materially different from such
statements or from any future results or performance implied thereby.
Factors that could cause the Company's results or performance to differ
materially from a conclusion, forecast or projection in the forward-looking
statements include, but are not limited to:

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of DRAXIS' products;

- DRAXIS' ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

DRAXIS and its products;

- factors beyond DRAXIS' control that could cause interruptions in

operations in its single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- DRAXIS' dependence on a small number of key customers;

- the disclosure of confidential information by DRAXIS' collaborators,

employees or consultants;

- the preservation of healthy working relationships with DRAXIS' union

and employees;

- DRAXIS' ability to grow the business;

- the fluctuation of DRAXIS' financial results and exchange and

interest rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against DRAXIS succeed;

- the volatility of the price of DRAXIS' common shares;

- market acceptance of DRAXIS' products;

- factors described under "Outlook" in DRAXIS' MD&A for the most recent

quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in

the Annual Report Form 20-F filed by DRAXIS with the United States

Securities and Exchange Commission and which is also filed as

DRAXIS' Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other
factors, and relating to DRAXIS generally, reference is made to DRAXIS'
most recent filings with the United States Securities and Exchange
Commission (available on EDGAR at http://www.sec.gov) and the filings made by
DRAXIS with Canadian securities regulators (available on SEDAR at
http://www.sedar.com). The forward-looking statements contained in this document
represent DRAXIS' expectations as at April 23, 2008. Unless otherwise
required by applicable securities laws, DRAXIS disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...

(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...

(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...

(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...

(Date:10/2/2017)... , Oct. 2, 2017 AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...